Codexis to Participate in Upcoming Healthcare Conferences

11/4/24 4:05:23 PM ET

Major Chemicals

Industrials

Get the next $CDXS alert in real time by email

REDWOOD CITY, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that management will participate in four upcoming investor conferences.

The Stifel 2024 Healthcare Conference (New York, NY)

Monday, November 18, 2024, at 2:25 pm ET, management will participate in a fireside chat

The Jefferies London Healthcare Conference (London, UK)

Tuesday, November 19, 2024, at 9:30 am GMT, management will participate in a fireside chat

The 15^th Annual Craig-Hallum Alpha Select Conference (New York, NY)

Tuesday, November 19, 2024, management will host 1x1 investor meetings

The Stephens Annual Investment Conference (Nashville, TN)

Thursday, November 21, 2024, at 12:00 pm CT, management will participate in a fireside chat

Live webcasts of each fireside chat will be available on the Investor Relations section of the Company's website, https://ir.codexis.com. A replay of each fireside chat will be archived for 90 days following the presentation date.

About Codexis

Codexis is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver^® technology platform to discover, develop and enhance novel, high-performance enzymes and other classes of proteins. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis™ manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit https://www.codexis.com.

For More Information

Investor Contact

Carrie McKim

(336) 608-9706

[email protected]

Media Contact

Lauren Musto

(650) 421-8205

[email protected]

Get the next $CDXS alert in real time by email

Recent Analyst Ratings for

$CDXS

Date	Price Target	Rating	Analyst
8/19/2024		Buy → Hold	The Benchmark Company
6/3/2024	$5.00	Buy	Jefferies
5/30/2024	$11.00	Overweight	Cantor Fitzgerald
2/29/2024		Hold → Buy	The Benchmark Company
11/7/2023		Buy → Hold	The Benchmark Company
8/7/2023	$21.00 → $4.00	Outperform → Market Perform	TD Cowen
5/9/2023		Buy → Neutral	H.C. Wainwright
3/31/2022	$35.00	Overweight	Piper Sandler

More analyst ratings

Codexis to Participate in Upcoming Healthcare Conferences

Chat with this insight

Recent Analyst Ratings for $CDXS

$CDXS Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director De Vre Raymond was granted 47,846 shares (SEC Form 4)

SEC Form 3 filed by new insider De Vre Raymond

Large owner Opaleye Management Inc. bought $72,720 worth of shares (25,000 units at $2.91) (SEC Form 4)

$CDXS Leadership Updates

Live Leadership Updates

Codexis Announces Appointment of Raymond De Vré, PhD, to Board of Directors

Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors

Codexis Increases Cash Reserves and Enhances Management Team to Fuel Growth of Company

$CDXS Market Insights

Live Market Insights

$CDXS Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$CDXS Large Ownership Changes

This live feed shows all institutional transactions in real time.

$CDXS SEC Filings

$CDXS Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Codexis Finalizes Purchase Agreement With Crosswalk Therapeutics For Gene Therapy Assets; Codexis Is Eligible To Receive Future Development And Commercial Milestone Payments In Addition To A Low-To-Mid Single-Digit Percentage Net Sales-Based Royalty

Cantor Fitzgerald Initiates Coverage On Codexis with Overweight Rating, Announces Price Target of $11

Codexis Successfully Synthesizes An Oligonucleotide Via An Enzymatic Route To Support RNA-Based Therapeutics Manufacturing

Codexis downgraded by The Benchmark Company

Jefferies resumed coverage on Codexis with a new price target

Cantor Fitzgerald initiated coverage on Codexis with a new price target

SEC Form SC 13G filed by Codexis Inc.

Amendment: SEC Form SC 13G/A filed by Codexis Inc.

SEC Form SC 13G filed by Codexis Inc.

SEC Form 8-K filed by Codexis Inc.

SEC Form 10-Q filed by Codexis Inc.

Codexis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

Large owner Opaleye Management Inc. bought $72,720 worth of shares (25,000 units at $2.91) (SEC Form 4)

Large owner Opaleye Management Inc. bought $249,147 worth of shares (85,000 units at $2.93) (SEC Form 4)

Large owner Opaleye Management Inc. bought $3,308,034 worth of shares (1,100,000 units at $3.01) (SEC Form 4)

$CDXS Press Releases

Fastest customizable press release news feed in the world

Codexis to Participate in Piper Sandler 36th Annual Healthcare Conference

Codexis Unveils Pioneering Enzymatic Synthesis Data to Enable the Future Manufacturing of RNAi Therapeutics

Codexis Announces Appointment of Raymond De Vré, PhD, to Board of Directors

$CDXS Financials

Live finance-specific insights

Codexis Unveils Pioneering Enzymatic Synthesis Data to Enable the Future Manufacturing of RNAi Therapeutics

Codexis TIDES Europe Presentations to Feature Next Step in Evolution of Enzymatic Synthesis for RNAi Therapeutics

Codexis Reports Third Quarter 2024 Financial Results

Recent Analyst Ratings for
$CDXS

$CDXS
Insider Trading

$CDXS
Leadership Updates

$CDXS
Market Insights

$CDXS
Analyst Ratings

$CDXS
Large Ownership Changes

$CDXS
SEC Filings

$CDXS
Insider Purchases

$CDXS
Press Releases

$CDXS
Financials